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There are six major steps in the management of patients with neuroendocrine
tumors (NETs) (carcinoids and pancreatic endocrine tumors). One of the steps
that is increasing in its importance is the need to assess primary tumor location
and tumor extent in these patients. Without such information, it is not possible
to adequately manage these patients. Conventional imaging studies (CT scan,
MRI, ultrasound, angiography), functional localization studies measuring hor-
monal gradients, endoscopic ultrasound, and most recently, somatostatin recep-
tor scintigraphy (SRS) with [1251-DTPA-DPhel]-octreotide have all been advo-
cated to localize NETs in different studies. Whereas it is now established that
for all NETs, except insulinomas, SRS has the greatest sensitivity, it remains
unclear whether this increased sensitivity translates into increased clinical use-
fulness. It, therefore, remains unclearbased on fiscal and clinical considerations
what should be the recommended algorithm for the use of the different local-
ization methods. To address this issue, we haverecentlyperformed two prospec-
tive studies on patients with gastrinomas. In this paper, the methods and results
ofeach are summarized andbased on theseresults, an algorithmforlocalization
studies in NETs is proposed. One study assessed therole ofSRS inmanagement
in 122 patients and shows that the use of SRS changed management in 47 per-
cent ofpatients according to six different criteria when the patients were strati-
fied according to their principal management problem. Determining whether
liver metastases were present is one of the major goals of tumor localization
studies and is frequently a source of confusion because of the difficulty in dis-
tinguishing small NETs liver metastases from hemangiomas. In the second
stucy, the ability of SRS and other tumor localization methods to distinguish
these two possibilities was assessed in 15 patients with small hemangiomas and
15 patients with small hepatic metastases (mean size 1.3 cm). SRS correctly
identified 93 percent of the patients with liver metastases and was not positive
in any patient with ahemangioma, suggesting it was not a liver metastases. SRS
had greater negative and positive predictive value than conventional studies.
Based on these two studies, and SRS's greater sensitivity and fiscal considera-
tions, it is proposed that SRS should be the initial tumor imaging study in all
NETs except insulinomas, and algorithms forthe use ofotherlocalization stud-
ies in both NETs and insulinomas are proposed.
INTRODUCTION
Carcinoid tumors and pancreatic endocrine tumors (PETs)b can both be considered
together as gastrointestinal neuroendocrine tumors (NETs) because oftheir common fea-
tures. These tumors have indistinguishable histologic features; are similar in their ability
a To whom all correspondence shouldbe addressed: RobertT. Jensen,NIHINIDDKJDDT, Building
10, Room 9C-103, 10 CENTER DR MSC 1804, Bethesda, MD 20892-1804. Tel.: 301-496-4201;
Fax: 301-402-0600; E-mail: robertj@bdglO.niddk.nih.gov.
bAbbreviations: PET, pancreatic endocrine tumor; NET, neuroendocrine tumor; SRS, somatostatin
receptor scintigraphy; EUS, endoscopic ultrasound.
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to synthesize multiple peptides; they both synthesize shared secreted proteins and cyto-
plasmic proteins such as chromogranin, synaptophysin and neuron-specific enolase; they
have similar biologic behavior, and the management considerations are similar with each.
[1-5]. The shared similar steps in management of NETs are summarized in Table 1. All
require the establishment ofthe diagnosis and determination ofwhether the tumor is asso-
ciated with a functional syndrome (i.e., gastrinoma, VIPoma, carcinoid syndrome, etc.).
Tumor localization and tumor extent are essential for planning the proper course ofman-
agement [1, 6] and will be discussed in detail below. Recently, it has become increasing-
ly apparent that inherited syndromes can be associated with either carcinoids (von
Recklinghausen's syndrome, multiple endocrine neoplasia-type I [MEN-I]) or PETs
(MEN-I, von Hippel-Landau disease, tuberous sclerosis, von Recklinghausen's syn-
drome), and theirrecognition is important because it alters management [7-9]. All patients
that have NETs have two treatment problems in thatifthe tumors are functional, treatment
must be directed at the hormone excess state and because most are malignant, treatment
must be directed at the tumor itself [1, 8-10] (Table 1). Lastly, all patients with NETs
require long-term follow-up because in many cases, even though the rate of growth is
slow, the true recurrence rate is unclear. For each of the management steps in Table 1, an
algorithm and fiscal comparison using different approaches could be done. In this article,
the analysis will be restricted to such considerations in NET tumor localization and extent.
PURPOSE OF NET LOCALIZATION STUDIES AND
LOCALIZATION METHODS USED
NET tumor localization studies are necessary for three primary reasons: first, to
determine resectability by determining if surgical resection is indicated, by excluding
extensive metastatic disease [6, 11-13]; second, to localize the primary tumor to increase
the likelihood of surgical resection [6, 14,15]; third, to assess tumor progression by deter-
mining growth to select the appropriate therapy [2, 6].
- Numerous imaging modalities have been widely used to localize NETs including con-
ventional imaging studies (ultrasound, computed tomographic scanning [CT scan], mag-
netic resonance imaging [MRI] and selective angiography) [6, 16], and functional local-
ization by measuring hormonal gradients either by portal venous sampling, or in hepatic
venous samples under basal conditions, or after secretin or calcium intra-arterial infusion
[17-19]. Recently, two newer methodologies, endoscopic ultrasound (EUS) [20] and
somatostatin receptor scintigraphy (SRS) [21-23] have been used. In terms ofthe purpos-
es ofimaging studies, the different modalities have varying utility. To determine resectabil-
ity, which is necessary in 95-100 percent of all patients with NETs, either conventional
imaging studies or SRS is useful. To determine primary tumor location, which is impor-
tant in all patients without extensive metastatic disease (90-95 percent ofinsulinomas [9],
Table 1. Steps in the management ofneuroendocrine tumors (NETs).
1. Make diagnosis (functional, etc.)
2. Determine tumor localization and extent
3. Establish presence or absence ofinherited syndrome
(MEN-I, von Recklinghausen's disease, von Hippel-Landau disease, etc.)
4. Treatment ofhormone-excess state (medical, surgical)
5. Treatment directed against tumor itself
6. Long-term follow-upJensen et al.: SRSfor GI endocrine tumor localization
Table 2. Cost ofvarious studies used in localization ofneuroendocrine tumors.
Washington, D.C. area University ofMichigan Average
Study:
CT scan $1000 $1948 $950-1000
MRI 1300 1300
Angiography 2294 2294
Portal venous
sampling 3257 3257
Intra-operative
ultrasound 400 400
Endoscopic
ultrasound 2500 $1130 1815
SRS $1984 $1984
University of Michigan data are from Reference [42].
20-50 percent ofother PETs [2, 9, 10]), conventional imaging studies, EUS, SRS, or hor-
monal gradients are commonly used [6, 17, 20, 21, 23, 24]. To assess tumor growth or
recurrence in patients with localized intra-abdominal recurrences (50 percent, Zollinger-
Ellison syndrome [25], 10 percent, other PETs [9, 10, 26]) conventional imaging studies,
EUS, or SRS can be used whereas to assess metastatic disease, which is required in40 per-
cent ofpatients with Zollinger-Ellison syndrome and 30-90 percent ofpatients with PETs
other than insulinomas, either conventional imaging or SRS are generally used [6, 21, 23,
27]. EUS or functional localization is, therefore, of potential use in less than half of all
patients with PETs in which identification ofthe primary or ofa localized recurrence is an
issue. In contrast, conventional imaging or SRS is of potential use in all patients where
localization studies are needed for either resectability, primary tumor localization or
assessment ofgrowth/recurrence.
CONSIDERATIONS IN CHOOSINGA GENERAL LOCALIZATION STUDY
Because EUS or functional location using sampling for hormonal gradients are use-
ful in only a subset ofthe indications for tumor localization studies, they will not be dis-
cussed further. Recent studies demonstrate that SRS is the most sensitive modality to
localize primary or metastatic carcinoid tumors and all PETs except insulinomas [21-23,
27-30]. However, for a number of reasons, it is difficult for the physician to define the
potential role of SRS in the management of a patient with a NET. First, increased sensi-
tivity cannot necessarily be equated with increased value. The detection of additional
metastases in a patient with numerous metastases may not change management, but
increases sensitivity. Similarly, the detection ofaprimary tumor in a nonoperative patient,
while increasing sensitivity, likely will not change management or have any clinical ben-
efit. Second, localization is performed fordifferentpurposes depending on the clinical set-
ting and, therefore, to evaluate its usefulness, the sensitivity needs to be assessed in dif-
ferent settings, which it rarely has been in different studies. For example, patients with or
without metastatic liverdisease or with or without MEN-I undergo localization studies for
different reasons [23, 31, 32]. Patients with livermetastases undergo imaging to determine
whether cytoreductive surgery should be considered [11, 33], tumoricidal treatment begun
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[2, 34, 35], liver transplantation considered [36-38], or to determine the response of some
tumoricidal treatment [2]. In contrast, in patients without hepatic metastases, imaging
studies are usually performed to localize a possible primary tumor that could be resected
[6, 39]. Patients with MEN-I with a functional PET that is not a gastrinoma undergo local-
ization studies to find which of numerous tumors is the functional one [17, 32]. In con-
trast, in patients with MEN-I with a nonfunctional PET or gastrinoma, some groups rec-
ommend routine surgery only if the tumor is greater than 2.5 cm [32, 40, 41]. Therefore,
imaging needs to be used that clearly establishs the size ofthe lesion. Third, the different
localization methods vary considerably in cost [42] (Table 2), and, therefore, fiscal con-
siderations are becoming increasingly a factor in which studies or combinations may be
done [31, 42]. In general, SRS costs twice as much as a CT scan and, in some cases MRI,
and generally costs slightly less than angiography (Table 2). The recent large NIH study
[23] in patients with gastrinomas demonstrated that the SRS was equal in sensitivity to the
combination ofall conventional imaging studies (ultrasound, CT scan, MRI, angiography;
total cost: $5500). Therefore, if SRS is also equally effective in management in these sit-
uations, it would also be more cost-effective than this combination ofconventional imag-
ing studies. In practice, for SRS to be completely cost-effective it must just be equal or
superior to a combination of two localization studies. Generally, only two localization
studies are performed in most patients with NETs. In the past, these studies usually were
ultrasound or CT and MRI or angiography and more recently, ultrasound, CT or MRI and
EUS [22, 29, 30, 43-46].
Whereas numerous studies have established the sensitivity of SRS, few studies have
attempted to assess the usefulness ofSRS in clinical management in sufficient numbers of
patients to allow acleardefinition ofits value compared to otherconventional localization
methods [23, 47, 48]. Recently two studies have been performed at the National Institutes
Table 3. NIH prospective study on effect ofSRS on clinical management.
A. Clinical categories ofpatients:
I. Patients undergoing an initial evaluation (preoperative initial evaluation category
[n= 17]).
II. Patients who had undergone a previous gastrinoma resection and were disease-free
and were undergoing yearly evaluation for possible recurrence (cured post-surgery
category [n = 18]).
III. Patients who had undergone resection but were not disease-free (not cured post-
resection [n = 48]).
IV. Patients who had not undergone surgical exploration either because ofconcomitant
medical conditions that either limited life expectancy or increased surgical risk (n = 7)
or because of associated MEN-I (n = 5) (no surgery category [n = 12]).
V. Patients with proven metastatic liver disease (metastatic liver disease category [n = 27]).
B. Criteria altering clinical management:
SRS changed management if SRS was:
I. The only imaging test identifying liver metastases.
II. The only study identifying liver metastases in more than one lobe.
III. The only study identifying a possible primary tumor in a patient who was a surgical
candidate or its detection changed management.
IV. The only study identifying bone metastases that changed treatment.
V. The only study identifying additional distant metastases that changed management.
VI. Useful in clarifying equivocal lesion(s) seen on conventional imaging studies
that resulted in altered management.
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of Health on patients with gastrinomas that address these issues. The remainder of this
paper will briefly review these studies and present an algorithm for tumor localization
studies based on extrapolation of these results and those from other studies on neuroen-
docrine tumors.
NIH PROSPECTIVE STUDY ON THE ABILITY OF SRS TO
ALTER MANAGEMENT IN PATIENTS WITH GASTRINOMAS
Methods in SRS management study
One hundred twenty-two consecutive patients with Zollinger-Ellison syndrome were
studied in this NIH prospective study [31]. Each patient was assigned to one of five dif-
ferent clinical categories (Table 3), because the rationale for doing localization studies
varies in different clinical situations. All patients first underwent conventional imaging
studies (ultrasound, CT, MRI, angiography, bone scan), and the clinical management was
decided. The SRS was then performed and clinical management redetermined. Based on
the six different criteria listed in Table 3, it was determined whether the SRS had changed
the clinical management in each of the five different clinical categories [31].
Results ofSRS management study
In all patients, CT demonstrated a lesion in 39 percent, MRI in 50 percent, any con-
ventional study including angiography in 62 percent, SRS in 62 percent and only SRS in
14 percent. The sensitivity of SRS varied from 0 percent in the cured group (category II,
Table 2) to 100 percent in the patients with metastatic liver disease (category V, Table 2).
The results forthe ability ofSRS to alter management in all patients (n = 122) and accord-
ing to the five different clinical categories are shown in Figure 1 stratified by the reason
that SRS changed clinical management. SRS changed management overall in 47 percent
ofthe patients (Figure 1 - top, any reason) and approximately equally affected each ofthe
clinical categories except the cured category (category II, Table 2).
The basis for SRS altering clinical management varied depending on the clinical cat-
egory (Figure 1). In patients in clinical category I for preoperative evaluation, SRS pri-
marily changed managementby clarifying equivocal lesions (41 percent) orbeing the only
study to identify aprimary lesion (6 percent). Figure 2 shows an example ofsuch apatient
in whom the MRI and all other imaging studies were negative preoperatively; however,
the SRS showed a pancreatic head lesion, and at surgery, the patient was cured after
removal of a 0.5 cm gastrinoma in a pancreatic head lymph node. In clinical category II
(cured patients), SRS changed management by clarifying equivocal lesions (22 percent)
from conventional imaging studies that could represent metastases or recurrence. A num-
ber ofthese lesions were questionable liver metastases, and one aspect ofthis is dealt with
in the second NIH study discussed below. SRS altered clinical management in 44 percent
ofpatients in clinical category III (not cured post-surgery) with the reasons being clarifi-
cation ofequivocal findings of conventional imaging studies (26 percent), the only study
to identify a recurrent gastrinoma leading to repeat exploration (22 percent), and identify-
ing new liver metastases in 4 percent. In clinical category IV (patients with no previous
surgery), SRS altered management in 50 percent by clarifying equivocal conventional
imaging studies (25 percent) or being the only study to demonstrate a primary lesion that
altered management. SRS altered management in 60 percent ofthepatients in the metasta-
tic liver disease category, primarily by clarifying equivocal lesions for conventional imag-
ing studies (32 percent), being the only modality to identify bilateral liver metastases
whose identification precluded surgery; being the only modality to identify any bone
metastases that led to institution of anti-tumor therapy (8 percent); and being the only
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Figure 1.Ability of SRS to change management in 122 patients with gastrinoma. One hundred
twenty-two consecutive patients with Zollinger-Ellison syndrome were divided into five different
clinical categories depending on the stage of their disease. The five categories were: Category I: 17
new patients evaluated preoperatively; Category II: 18 patients previously cured by gastrinoma
resection and undergoing yearly re-evaluation for recurrence; Category III: 50 patients post noncu-
rative resection undergoing yearly re-evaluation; Category IV: 12 patients who did not undergo
surgery either because of accompanying medical conditions or who had MEN-I; Category V: 25
patients with liver metastases. Each patient first underwent conventional imaging studies (CT, MRI,
angiography and ultrasound) and the management was decided. SRS was then performed and based
on the six reasons (Table 3) shown it was determined whether SRS had changed management. With
each of the six different reasons for possibly changing management, the proportion of patients in
each clinical category in which management was changed is indicated. Data are from Reference [31].Jensen et al.: SRSfor GI endocrine tumor localization
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Figure 2. MRI and SRS in a patient with Zollinger-Ellison syndrome prior to surgery. The
MRI (top) was negative as were the other conventional imaging studies; however, SRS showed a
pancreatic head tumor (lower) which was subsequently removed at surgery. This patient is an exam-
ple of SRS changing management in that it was the only localization study showing the gastrinoma
prior to surgery (Reason #1, Figure 1; Table 3).
modality to identify additional metastases that altered management (8 percent). An exam-
ple ofthe lattercategory is shown in Figure 3 for apatientcomplaining ofupperbackpain
with metastatic gastrinoma. The bone scan showedL-3, rib and left scapula metastases but
no thoracic spine metastases or upper lumbar vertebral metastases that could explain the
upperbackpain. SRS demonstrates thoracic and L-1 vertebral metastases. Thepatient was
treated with local radiation, and the chemotherapy was changed.
Patients in whom SRS changed management (n = 57) did not differ from patients in
whom it did not change management (n = 65) in various demographic features (age, gen-
der, MEN-I present, disease duration), whether it was the initial patient evaluation or not,
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Figure 3.Ability ofbone scan and SRS to identify bone metastases in a patient with metasta-
tic gastrinoma to the liver with upper back pain. The bone scan (left panel) showed (arrows) a
left scapula and two rib metastases as well as a bone metastasis in L-3, but none in the thoracic or
upper lumbar spine where the patient had pain. The SRS (right panel) demonstrates both thoracic
and upper and lower lumbar spine metastases (arrows) as well as bone metastases to the left scapu-
la and left pelvis. The primary tumor was also seen in the pancreatic tail (broken arrow) as well as
the large numbers of liver metastases. The patient was treated with radiation to the area of the tho-
racic and L-1 spinal metastases, and the chemotherapy was changed. This patient represents an
example ofSRS altering managementby identification ofadditional metastases whichchangedclin-
ical management (Reason #5, Figure 1; Table 3).
laboratory characteristics (BAO, MAO, fasting gastrin level), in whether the patients had
or had not undergone a previous gastrinoma resection, or whether liver metastases were
present or absent (p = .06). SRS was more likely to change management in patients with
any positive conventional imaging study (p < .001), a possible primary lesion on a con-
ventional imaging study (p < .001) or possible liver metastases on conventional imaging
studies (p < .0001).
CONCLUSIONS OF THE NIH SRS MANAGEMENT STUDY
It was concluded that SRS, because of its ability to alter clinical management com-
bined with its high sensitivity shown both in this study [31] and in previous studies [21-
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23, 28, 29, 45, 46, 49-51], high specificity [21, 23, 27], and simplicity and ability to image
the entire body, should be the initial imaging modality for patients with gastrinoma.
Because SRS is as sensitive as all conventional imaging studies combined, and two con-
ventional studies are usually performed, the initial use of SRS based on sensitivity alone
is cost-effective. Furthermore, because somatostatin receptor density is similarly high in
all other NETs except insulinomas [21, 22, 27, 52] and because of their similar biologic
behavior to gastrinomas [1, 2], it is likely that these conclusions also apply to less com-
mon PETs and carcinoid tumors [31]. A recent review [53], presents data from a few stud-
ies that demonstrate SRS did not detect a number of small metastases in the liver in
patients with metastatic carcinoids. Whether this result is due to the small size of the
metastases or is specific for carcinoid tumors is presently unknown.
In the above NIH study, the main reason for SRS changing clinical management was
the clarification of equivocal lesions on conventional imaging studies (29 percent). This
was more than twice as common a reason for changing management than any other factor
and made up more than 50 percent ofthe changes in management in each clinical catego-
ry (Figure 1). One ofthe main lesions requiring clarification was the question ofpossible
liver metastases identified on CT, MRI (particularly the STIR images [short TI inversion-
recovery pulse sequences]) or angiography. One ofthe main reasons for this confusion is
that liver metastases from NETs are highly vascular [16], may be few in number and in
many patients are small when first discovered (<1-2 cm); therefore, they may be very dif-
ficult to differentiate from other small vascular tumors of the liver, particularly heman-
giomas, using the standard imaging techniques (MRI, CT, angiography) [54-56].
Cavernous hemangiomas ofthe liver are the most common benign tumor ofthe liver,
occurring in 7.5-15 percentofautopsy cases [57, 58]. Cavernous hemangiomas canbe dif-
ficult to distinguish from small metastases in patients with malignant NETs because they
also are hypervascular and may be multiple in 10-50 percent of cases [57, 59].
Investigations such as 99MTc-labeled red blood cell scintigraphy, heavily T2-weighted
MRI, and dynamic bolus-enhanced CT or MRI are frequently falsely negative in heman-
giomas less than 1.5 cm in diameter [54, 56, 60-63]. For example, in one recent study
99MTc RBC scanning with SPECT imaging only detected 58 percent of 24 hemangiomas
1-1.9 cmin diameter [54]. There havebeen anumberofreports ofpatients thoughtto have
hepatic hemangiomas that later proved to be NETs [64-66]. In our study on the role of
SRS in management presented above, one patient had both a liver metastasis and a hepat-
ic hemangioma verified at surgical exploration, and although both were seen on MRI and
angiography, only the metastasis was seen on the SRS. This case raised the possibility that
the SRS might not generally identify hepatic hemangiomas, why it would identify almost
all liver metastases and, thus, might be able to distinguish these two vascular abnormali-
ties. High densities of somatostatin receptors are found in intestinal veins in patients with
inflammatory bowel disease and in peritumoral veins, but not in normal veins orothervas-
cular structures [67, 68]; however, it is unknown if an increased density of somatostatin
receptors occurred in hemangiomas. To examine this possibility and to determine whether
SRS was superior to other imaging studies in distinguishing whether small hepatic vascu-
lar lesions in patients with gastrinomas were metastases or hemangiomas, an additional
study was performed [56].
489Jensen et al.: SRSfor GI endocrine tumor localization
ZES
(29 Patients with 76 vascular liver lesions)
Hepatic Metastases Hepatic Hemanglomas
(n = 15 pts with 45 lesions) (n = 15 pts with 31 lesions)
10 20 30 40 50 60 70 80 90 100
z ** 2 Any lesion
2 ** * Correctly Identified
/////34**
*4**
//////////////////////73 _*~~**
4~~~~~~~8
51 **
t ft Alt nA, .^ ^ ^An 4 10 20 30 40 50 60
Percet
70 80 90 100
10 20 30 40 50 60 70 80 90 100
/ 29 **
6 **
:71I
0**
10 20 30 40 50 60 70 80 90 100
Percent
Figure 4.Ability of conventional imaging studies (CT, MRI, angiography) or SRS to either
identify any hepaticlesion orcorrectly identify it as a metastasis orhemangioma in 15 patients
with hepatic metastases and 15 patients with hepatic hemangiomas. All patients had Zollinger-
Ellison syndrome. There were 76 vascular hepatic lesions in these 29 patients including 45 metas-
tases and 31 hemangiomas. One patient had both a hemangioma and a hepatic metastasis. Results
are the percent oflesionsexamined with the indicatedimaging study which werepositive in the indi-
cated category. Zero percent ofthe hepatic hemangiomas gave a positive SRS result; therefore, 100
percent were correctly identified as not metastases. Results are from [56].
NIH STUDY OF THE ABILITY OF SRS AND CONVENTIONAL IMAGING
STUDIES (CT, MRI, ANGIOGRAPHY) TO DISTINGUISH HEPATIC
HEMANGIOMAS FROM METASTASES IN PATIENTS WITH GASTRINOMAS
Methodsfor NIH SRS hemangioma study.
Of 137 consecutive patients with gastrinoma admitted to the NIH, 29 patients were
found to have small hypervascular liver lesions (< 3 cm diameter; mean: 1.3 cm) with less
than five lesions per hepatic lobe or nine lesions per liver, and these patients were includ-
ed in this study. Twenty-six of these patients had multiple previous NIH admissions
(mean: seven admissions), and three patients were being investigated for the first time.
Fifteen patients including three new patients were determined to have hepatic heman-
giomas by the presence of one or more of the following: hemangioma observed during
surgery (n = 3), by biochemical evidence of cure of the Zollinger-Ellison syndrome after
resection of an extrahepatic gastrinoma (n = 7) or by the absence of growth of the lesion
on standard imaging studies after a mean follow-up of four years (n = 5). In 15 patients,
the hepatic lesions were shown to be metastatic tumor histologically by a CT- or ultra-
sound-guided percutaneous liver biopsy or during laparotomy. One patient was found to
have both a hepatic hemangioma and a single liver metastasis. Each of the 29 patients
CT
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Angio
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**p cO.01
490
F-F %.* IJensen et al.: SRSfor GI endocrine tumor localization
MRI Angio SRS
_|_ _ ~~~~~~~~~~Liver
.......
Figure 5. MRI, angiography and SRS in a patient with Zollinger-Ellison syndrome. The MRI
(left panel) and angiography (middle panel) show ahepatic vascularlesion (arrows) that could
represent a metastasis from the gastrinoma. The SRS (right panel) was negative. This hepatic
lesion was determined to represent a hemangioma because with long-term follow-up it did not
increase in size and the patient remained cured post resection ofa duodenal tumor with normal fast-
ing gastrin levels and a negative secretin test [97].
underwent a CT scan, MRI, selective angiography and SRS. A single radiologist who did
not know the diagnosis read each film, determining whether any hepatic lesion could be
seen and whether it was a hemangioma, metastasis, or whether it could not be determined
which of the two vascular lesions it was. The CT criteria [60, 61, 69-71] and selective
angiography criteria [72-74] were those previously described. On MRI both metastases
and hemangiomas were oflow signal intensity onTI-weighted images andbright on STIR
images. Extreme brightness compared to the kidney or spleen was more suggestive of
hemangioma.
Results ofSRS hemangioma study
There were 31 hemangiomas in the 15 patients with a mean number of 2.1/patient
(range: 1-9) with a mean size of 1.3 + 0.1 cm (range: 0.5 - 2.8 cm) with 60 percent less
than 1 cm. There were 45 metastases in 15 patients with a mean of 2.5 lesions/patient
(range: 1-8), with a mean size of 1.3 + 0.1 (range: 0.5 - 3 cm) (Figure4). Thedata, whether
analyzed on a per patient basis or a per lesion basis (Figure 4), showed similar results.
SRS detected a hepatic metastases in 93 percent of patients with liver metastases. In
patients with metastases, SRS and angiography were not significantly different in identi-
fying the number oflesions, and both were significantly better than CT or MRI (Figure 4,
left panel). However, for correctly identifying a lesion as a metastasis, the SRS correctly
identified 84 percent of all metastases in 93 percent of the patients and was significantly
better than any ofthe other studies or a combination ofall ofthe studies (p < .01) (Figure
4, left). In contrast, SRS was negative in all 15 patients with hemangiomas. Angiography
and MRI both identified hepatic vascular lesions in over 70 percent ofpatients with hepat-
ic hemangiomas. In contrast, angiography correctly identified 77 percent as heman-
giomas, whereas CT and MRI correctly identified less than 10 percent (Figure 4, right
panel). Figure 5 shows anexample ofsuch apatientin which the MRI andangiogramboth
demonstrate a possible hepatic metastasis, whereas the SRS was negative. This patient
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Figure 6. Specificity, positive and negative predictive values ofdifferent imaging modalities in
detecting liver metastases in 29 patients with Zollinger-Ellison syndrome and hypervascular
hepatic lesions seen on any imaging study which could be either metastases or hemangiomas.
The specificity, positive and negative predictive values are based on the lesion correctly identified
in Figure 4. Data are from [56].
was biochemically cured post-gastrinoma resection and has remained disease-free for two
years, confirming that the hepatic vascular lesion is a hemangioma.
SRS was superior to all of the other studies for negative and positive predictive val-
ues and equal to CT scanning and angiography in terms of specificity (Figure 6).
Conclusions ofNIH SRS hemangioma study
SRS is an excellent imaging modality fordistinguishing small vascular hepatic metas-
tases in patients with gastrinomas from small hemangiomas. Because hepatic metastases
inpatients with gastrinoma are similar in terms ofdensity ofsomatostatin receptors, hyper-
vascularity and CT, MRI and angiographic appearance of those occurring in other malig-
nant NETs, SRS will likely be similarly useful in these syndromes. The practical ability of
SRS to make this distinction and affect clinical management was shown in the previous
study in which more than 50 percent of all the changes in management caused by SRS
were due to clarification ofequivocal lesions and at least 50 percent of these were related
to equivocal hepatic vascular lesions.
Specificity
CT Scan
MRI
Angiography
SRS
80 90 100
492
I...- * *
I***
IlJensen et al.: SRSfor GI endocrine tumor localization
CONCLUSIONS FROM THE NIH SRS STUDIES AND PROPOSAL OF AN
ALGORITHM FOR TUMOR LOCALIZATION IN PATIENTS WITH
NEUROENDOCRINE TUMORS (EXCEPT INSULINOMAS)
AND IN PATIENTS WITH INSULINOMAS
The two NIH studies presented above clearly establish thatthe use ofSRS affects clin-
ical management in 47 percent of the cases [31] and is particularly helpful in clarifying
equivocal results from conventional imaging studies, especially in regard to the identity of
small vascular metastasis in the liver [56]. In the management study, the nearly one-halfof
all cases in which SRS altered management represents a measure ofthe clinical gain over
existing conventional imaging studies by the use of SRS. In numerous studies in patients
with different NETs except insulinomas, SRS has been shown to have either greater sen-
sitivity than any conventional imaging study (i.e., ultrasound, CT scan, MRI, selective
angiography) or is at least equal or better than all imaging studies combined [21, 23, 28-
31, 44, 48, 56]. Therefore, performing just the SRS would be a much more cost-effective
approach than performing each of the conventional imaging studies (Table 2) [31, 42].
Because of its increased sensitivity and ability to image the entire body, SRS gives infor-
mation on the location of the primary tumor, possible regional tumor metastases and dis-
tal metastases. Therefore, it provides at least equal information to the conventional imag-
ing studies in patients in which it did not change management, as well as the additional
information it gives in patients in which it did change management. Lastly, the specificity
| Neuroendocrine Tumor (Except insulinoma)
No Liver Metastases I
a (PET) Carcinoid
If limited; do MRI,
angiography, surgery
If extensive; then
do CT or Ultrasound-
guided biopsy. C
MRI for follow-up
Angiography +
alcium or Secretin
To Surgery I
Figure 7. Algorithm for tumor localization in a patient with a neuroendocrine tumor (pancre-
atic endocrine tumor [PET], carcinoid tumor) that is not an insulinoma. Abbreviations: SRS,
somatostatin receptor scintigraphy (see text for full explanation).
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I INSULINOMA
Figure 8. Algorithm for tumor localization in a patient with an insulinoma (see text for full
explanation).
ofSRS appears generally excellent [21, 23, 27] although it has not been carefully studied.
SRS has been reported to be positive in various thyroid diseases [21, 27, 75], granulo-
matosis diseases [21, 27, 76], and some arthrides [21, 27, 77]; however, this appears not to
limit its usefulness inpatients with NETs in various large studies [21, 23, 28, 31]. The con-
clusions drawn from the studies ofgastrinoma can likely be extended to otherPETs except
insulinomas and also to carcinoid tumors because of the similar rate of occurrence of
somatostatin receptors in these different tumors and their similar biologic behavior [1, 2,
7, 8]. Insulinomas are excluded because only 70 percent have somatostatin receptors [21,
22], and they also may possess somatostatin receptors that do not bind octroetide, espe-
cially subtypes sstl and sst4, and only 14-50 percent are localized by SRS in some stud-
ies [22, 27, 30]. Each of the other neuroendocrine tumors can be malignant [21, 22, 78],
and the treatment decisions are similar to that for gastrinomas in similar stages of their
management [1, 2, 8, 26, 79]. Based on these considerations, the tumor localization
approach as shown in Figure 7 for all NETs except insulinomas is recommended; and for
insulinomas, the algorithm shown in Figure 8 is recommended.
For all NETs except insulinomas the SRS should be the initial localization study
based on its sensitivity, specificity, ability to image the entire body and cost-effectiveness.
If liver metastases are seen on the SRS and if they are extensive in both lobes, which is
the case in 80-90 percent ofpatients with hepatic metastases, then surgical resection is not
generally a consideration [1, 2, 8, 11-13, 33, 80]. To confirm the diagnosis, a CT- or ultra-
sound-guided biopsy can be performed (Figure 7). It is not yet established how changes
in size or intensity ofthe SRS image relates to change in tumor size assessed by measur-
ing tumor growth with conventional imaging studies; therefore, we recommend that if
liver metastases are seen on SRS, a conventional imaging study be performed to facilitate
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follow-up assessment of tumor growth. In our experience, the MRI, especially the STIR
images, gives the best results and is the most sensitive [6, 55]. Ifthe metastases are limit-
ed and cytoreductive surgery is considered [1, 2, 8, 11-13, 33, 80], we would recommend
selective angiography and MRI to define the relationship of the metastases to the vascu-
lature and clearly define the tumor size and location (Figure 7). A recent study [24]
demonstrates that the use ofthe intra-arterial injection ofsecretin during angiography with
hepatic venous sampling can be useful and will change management in 22 percent ofcases
with limited or equivocal hepatic lesions in patients with gastrinomas. This study [24] did
not include the use of SRS, and it is unclear whether intra-arterial secretin with hepatic
venous gastrin gradients would be as useful if the SRS did not clarify the situation.
Therefore, until this study is done it is not recommended routinely.
If SRS does not show liver metastases in a non-insulinoma NET, no other imaging
studies need to be performed to exclude liver metastases because the SRS detected 92 per-
cent ofpatients with liver metastases, and the addition ofall conventional imaging studies
only increased the sensitivity by 4 percent in one large study [23]. However, additional
studies to localize the primary tumor may be indicated (Figure 7). Ifthe primary tumor is
not localized on SRS inpatients with aPET, endoscopic ultrasound shouldbe the nextpro-
cedure performed. EUS localizes almost all pancreatic PETs although it may miss as high
as 50 percent of duodenal PETs [43, 81, 82]. If it is negative, angiography with selective
intra-arterial injection of secretin or calcium and hepatic venous sampling should be per-
formed [17-19]. At surgery, intraoperative ultrasound [14, 83] should be used and in the
case of gastrinomas a duodenal exploration with duodenotomy [84, 85] is essential, with
priortransillumination ofthe duodenum to assist in theplacement ofthe duodenotomy and
tumor localization [86]. In a patient with a carcinoid tumor with no liver metastases, CT
or MRI are indicated to localize the primary tumor and its extent (Figure 7).
In patients with insulinomas, MRI should be the initial imaging study to exclude liver
metastases that occur in 5-15 percent of patients with insulinomas in different series [9,
87-91]. In the algorithm (Figure 8), we have recommended an MRI be done because we
find it easier to see PET metastases to the liver on the STIR sequences than with CT. Ifno
liver metastases are seen, the localization study ofchoice is endoscopic ultrasound, which
is reported to identify an insulinoma in 77-93 percent of patients [20, 30, 92, 93]. If this
is negative, angiography with intra-arterial calcium injection with hepatic venous sam-
pling for insulin gradients should be performed, because it is recently reported to be pos-
itive in 83-88 percent ofcases [19, 94, 95]. At surgery, intra-operative ultrasound has been
shown to be particularly helpful in localizing intrapancreatic endocrine tumors such as
insulinomas and should be used [14, 80, 83, 96].
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